Human Genome Sciences Inc (HGSI): Today's Featured Drugs Loser

Human Genome ( HGSI) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 1.5%. By the end of trading, Human Genome fell 16 cents (-1.2%) to $13.10 on light volume. Throughout the day, 3.3 million shares of Human Genome exchanged hands as compared to its average daily volume of 6.9 million shares. The stock ranged in price between $13.10-$13.28 after having opened the day at $13.20 as compared to the previous trading day's close of $13.26. Other company's within the Drugs industry that declined today were: Prima Biomed Ltd. ADR ( PBMD), down 16.1%, Alexza Pharmaceuticals ( ALXA), down 12.3%, Aegerion Pharmaceuticals ( AEGR), down 10.9%, and Opexa Therapeutics ( OPXA), down 10.9%.

Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. Human Genome has a market cap of $2.67 billion and is part of the health care sector. Shares are up 81.1% year to date as of the close of trading on Wednesday. Currently there are seven analysts that rate Human Genome a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Human Genome as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally weak debt management.

On the positive front, Tengion ( TNGN), up 30.4%, Biostar Pharmaceuticals ( BSPM), up 15.7%, Osiris Therapeutics ( OSIR), up 14.1%, and Complete Genomics ( GNOM), up 12.8%, were all gainers within the drugs industry with Pfizer ( PFE) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).